Literature DB >> 19240234

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

Lindsey Enewold1, Kangmin Zhu, Elaine Ron, Aizen J Marrogi, Alexander Stojadinovic, George E Peoples, Susan S Devesa.   

Abstract

Thyroid cancer incidence has been rising in the United States, and this trend has often been attributed to heightened medical surveillance and the use of improved diagnostics. Thyroid cancer incidence varies by sex and race/ethnicity, and these factors also influence access to and utilization of healthcare. We therefore examined thyroid cancer incidence rates by demographic and tumor characteristics based on 48,403 thyroid cancer patients diagnosed during 1980-2005 from the Surveillance, Epidemiology and End Results program of the National Cancer Institute. The rates varied by histologic type, sex, and race/ethnicity. Papillary carcinoma was the only histologic type for which incidence rates increased consistently among all racial/ethnic groups. Subsequent analyses focused on the 39,706 papillary thyroid cancers diagnosed during this period. Papillary carcinoma rates increased most rapidly among females. Between 1992-1995 and 2003-2005, they increased nearly 100% among White non-Hispanics and Black females but only 20% to 50% among White Hispanics, Asian/Pacific Islanders, and Black males. The increases were most rapid for localized stage and small tumors; however, rates also increased for large tumors and tumors of regional and distant stage. Since 1992-1995, half the overall increase in papillary carcinoma rates was due to increasing rates of very small (<or=1.0 cm) cancers, 30% to cancers 1.1 to 2 cm, and 20% to cancers>2 cm. Among White females, the rate of increase for cancers>5 cm almost equaled that for the smallest cancers. Medical surveillance and more sensitive diagnostic procedures cannot completely explain the observed increases in papillary thyroid cancer rates. Thus, other possible explanations should be explored.

Entities:  

Mesh:

Year:  2009        PMID: 19240234      PMCID: PMC2676561          DOI: 10.1158/1055-9965.EPI-08-0960

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  34 in total

1.  A pooled analysis of case-control studies of thyroid cancer. II. Menstrual and reproductive factors.

Authors:  E Negri; L Dal Maso; E Ron; C La Vecchia; S D Mark; S Preston-Martin; A McTiernan; L Kolonel; Y Yoshimoto; F Jin; G Wingren; M Rosaria Galanti; L Hardell; E Glattre; E Lund; F Levi; D Linos; C Braga; S Franceschi
Journal:  Cancer Causes Control       Date:  1999-04       Impact factor: 2.506

2.  Temporal trends for thyroid carcinoma in Australia: an increasing incidence of papillary thyroid carcinoma (1982-1997).

Authors:  John R Burgess
Journal:  Thyroid       Date:  2002-02       Impact factor: 6.568

3.  Primary malignancies of the thyroid: epidemiologic analysis of the Florida Cancer Data System registry.

Authors:  Z D Mulla; C E Margo
Journal:  Ann Epidemiol       Date:  2000-01       Impact factor: 3.797

4.  Thyrotropin is a potent growth factor for normal human thyroid cells in primary culture.

Authors:  P P Roger; J E Dumont
Journal:  Biochem Biophys Res Commun       Date:  1987-12-16       Impact factor: 3.575

Review 5.  Invited commentary: ecologic studies--biases, misconceptions, and counterexamples.

Authors:  S Greenland; J Robins
Journal:  Am J Epidemiol       Date:  1994-04-15       Impact factor: 4.897

6.  Graphical presentation of trends in rates.

Authors:  S S Devesa; J Donaldson; T Fears
Journal:  Am J Epidemiol       Date:  1995-02-15       Impact factor: 4.897

7.  Thyroid cancer in Connecticut, 1935-1975: an analysis by cell type.

Authors:  L M Pottern; B J Stone; N E Day; L W Pickle; J F Fraumeni
Journal:  Am J Epidemiol       Date:  1980-12       Impact factor: 4.897

8.  Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III).

Authors:  Joseph G Hollowell; Norman W Staehling; W Dana Flanders; W Harry Hannon; Elaine W Gunter; Carole A Spencer; Lewis E Braverman
Journal:  J Clin Endocrinol Metab       Date:  2002-02       Impact factor: 5.958

9.  Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies.

Authors:  E Ron; J H Lubin; R E Shore; K Mabuchi; B Modan; L M Pottern; A B Schneider; M A Tucker; J D Boice
Journal:  Radiat Res       Date:  1995-03       Impact factor: 2.841

10.  Thyroid cancer in the Middle Eastern population of California.

Authors:  Kiumarss Nasseri
Journal:  Cancer Causes Control       Date:  2008-06-10       Impact factor: 2.506

View more
  295 in total

1.  Thyroid cancer presentation and treatment in the United States.

Authors:  Lindsey Enewold; Linda C Harlan; Jennifer L Stevens; Elad Sharon
Journal:  Ann Surg Oncol       Date:  2014-11-01       Impact factor: 5.344

2.  Prognostic significance of Tiam1 expression in papillary thyroid carcinoma.

Authors:  Chuen Hsueh; Jen-Der Lin; Chia-Fen Yang; Yu-Sun Chang; Tzu-Chieh Chao; Jui-Hung Sun; I-Chin Wu; Ngan-Ming Tseng; Shir-Hwa Ueng
Journal:  Virchows Arch       Date:  2011-11-11       Impact factor: 4.064

3.  The relationship between glucose metabolism disorders and malignant thyroid disease.

Authors:  Ayse Ocak Duran; Cüneyd Anil; Alptekin Gursoy; Aslı Nar; Ozden Altundag; Neslihan Bascil Tutuncu
Journal:  Int J Clin Oncol       Date:  2012-06-30       Impact factor: 3.402

Review 4.  Exposing the thyroid to radiation: a review of its current extent, risks, and implications.

Authors:  Bridget Sinnott; Elaine Ron; Arthur B Schneider
Journal:  Endocr Rev       Date:  2010-07-21       Impact factor: 19.871

5.  Variation by ethnicity in the prevalence of congenital hypothyroidism due to thyroid dysgenesis.

Authors:  Sophie Stoppa-Vaucher; Guy Van Vliet; Johnny Deladoëy
Journal:  Thyroid       Date:  2010-11-08       Impact factor: 6.568

6.  Promoter methylation of p16 and RASSF1A genes may contribute to the risk of papillary thyroid cancer: A meta-analysis.

Authors:  Jia-Li Jiang; Gui-Lan Tian; Shu-Jiao Chen; L I Xu; Hui-Qin Wang
Journal:  Exp Ther Med       Date:  2015-07-24       Impact factor: 2.447

7.  Anaplastic Thyroid Carcinoma, Version 2.2015.

Authors:  Robert I Haddad; William M Lydiatt; Douglas W Ball; Naifa Lamki Busaidy; David Byrd; Glenda Callender; Paxton Dickson; Quan-Yang Duh; Hormoz Ehya; Megan Haymart; Carl Hoh; Jason P Hunt; Andrei Iagaru; Fouad Kandeel; Peter Kopp; Dominick M Lamonica; Judith C McCaffrey; Jeffrey F Moley; Lee Parks; Christopher D Raeburn; John A Ridge; Matthew D Ringel; Randall P Scheri; Jatin P Shah; Robert C Smallridge; Cord Sturgeon; Thomas N Wang; Lori J Wirth; Karin G Hoffmann; Miranda Hughes
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

Review 8.  New insights in risk stratification of differentiated thyroid cancer.

Authors:  Maria Papaleontiou; Megan R Haymart
Journal:  Curr Opin Oncol       Date:  2014-01       Impact factor: 3.645

9.  Changing patterns in thyroid cancer incidence and mortality in the Slovak Republic by histological type and age.

Authors:  Martina Ondrusova; Karol Kajo; Dalibor Ondrus
Journal:  Int J Clin Oncol       Date:  2013-11-09       Impact factor: 3.402

10.  Rising incidence of thyroid cancer in Singapore not solely due to micropapillary subtype.

Authors:  J H Shulin; J Aizhen; S M Kuo; W B Tan; K Y Ngiam; R Parameswaran
Journal:  Ann R Coll Surg Engl       Date:  2018-03-15       Impact factor: 1.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.